Further, tissue targeting or site-specific delivery of drug loaded exosomes can be explored by adding a wide variety of tumor-targeting ligands such as antibodies (e.g., VEGF, EGFR), peptides (e.g., transferrin, integrins, Her2), or receptor-targets (e.g., FA, biotin and hyaluronic acid) to the milk exosomes. This evidence concerns the gene EGFR and neoplasm.